The Long Run with Luke Timmerman
Ep151: Shelley Force Aldred and Nathan Trinklein on Bispecific Antibodies for Cancer
Dec 26, 2023
Shelley Force Alderd and Nathan Trinklein talk about developing bispecific antibodies for cancer, discussing their journey from academia to entrepreneurship, the mechanism of action of T-cell engagers, challenges in developing therapies for solid tumors, and the importance of strategic company structuring for new drug candidates.
01:03:55
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Bispecific antibodies offer diverse therapeutic avenues in cancer treatment.
- Synergistic collaboration and persistence are crucial for entrepreneurial success.
Deep dives
Shelley, Nathan, and Their Company Rondo Therapeutics' $67 Million Series A Funding and Mission Statement
Shelley Force, Aldred, and Nathan Trinkline, co-founders of Rondo Therapeutics, raised $67 million in a Series A financing. The company aims to develop bi-specific T-cell engaging antibodies to combat solid tumors.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
